Skip to main content

What the FDA labels say about taking them together

Lamivudine and ribavirin

Ribavirin's FDA label of February 6, 2024 names lamivudine in its drug interactions section; the lamivudine labels PlainMeds reads (2) do not name ribavirin. The ribavirin label: “Inhibitors (NRTIs) In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.”

Check it at the source: the lamivudine FDA label on DailyMed (effective January 5, 2026, Strides Pharma Science Limited); the ribavirin FDA label on DailyMed (effective February 6, 2024, Aurobindo Pharma Limited).

What does the lamivudine label say about ribavirin?

Lamivudine's label (effective January 5, 2026) and its 1 other brand-application label do not name ribavirin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lamivudine), Strides Pharma Science Limited, effective January 5, 2026 (SPL set ac824c7e-9c9f-487b-ad2f-d50eaef5cbda), via openFDA; the full label on DailyMed

What does the ribavirin label say about lamivudine?

Ribavirin label, drug interactions

Inhibitors (NRTIs) In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.

Ribavirin label, warnings and precautions

All 14 patients were on NRTIs, including stavudine, didanosine, abacavir, zidovudine, and lamivudine.

Source: FDA drug label (Ribavirin), Aurobindo Pharma Limited, effective February 6, 2024 (SPL set eee304d0-c2ea-44f4-97d9-92a414d31b6c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Lamivudine generic labelers
1Ribavirin generic labelers
LamivudineRibavirin
Labeled forHIV, Hepatitis BHepatitis C
Boxed warningYesYes
Pharmacy cost (NADAC)$0.489 per tablet 150 mg tablet$0.451 per tablet 200 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?